Assembly Biosciences, INC Form 4 insider transactions

NASDAQ
William E. Delaney IV, Chief Scientific Officer of Assembly Biosciences, received 20,000 stock options on March 29, 2024, according to a Form 4 filing.
NASDAQ
Assembly Biosciences CEO Jason Okazaki sold 354 shares to cover tax obligations related to vested restricted stock units and received 65,000 stock options.
NASDAQ
Assembly Biosciences CEO Jason A. Okazaki sold 392 shares of common stock on March 27, 2024, to cover tax withholding obligations related to the vesting and settlement of restricted stock units.